BioDelivery Sciences International PT Raised to $18.00 (BDSI)
Equities research analysts at Ladenburg Thalmann boosted their target price on shares of BioDelivery Sciences International (NASDAQ:BDSI) to $18.00 in a research note issued to investors on Monday. The firm currently has a “buy” rating on the stock. Ladenburg Thalmann’s price target would indicate a potential upside of 80.00% from the stock’s previous close.
A number of other firms have also recently commented on BDSI. Analysts at Roth Capital raised their price target on shares of BioDelivery Sciences International to $15.50 in a research note on Monday. They now have a “buy” rating on the stock. Separately, analysts at Laidlaw reiterated a “buy” rating on shares of BioDelivery Sciences International in a research note on Monday. They now have a $15.00 price target on the stock. Finally, analysts at William Blair reiterated an “outperform” rating on shares of BioDelivery Sciences International in a research note on Monday. They now have a $23.00 price target on the stock. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $19.25.
Shares of BioDelivery Sciences International (NASDAQ:BDSI) traded down 1.50% on Monday, hitting $9.85. 3,068,688 shares of the company’s stock traded hands. BioDelivery Sciences International has a 52 week low of $3.86 and a 52 week high of $10.20. The stock’s 50-day moving average is $8.96 and its 200-day moving average is $7.63. The company’s market cap is $477.2 million.
BioDelivery Sciences International (NASDAQ:BDSI) last announced its earnings results on Friday, May 9th. The company reported ($0.11) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.15) by $0.04. The company had revenue of $20.69 million for the quarter, compared to the consensus estimate of $11.60 million. Analysts expect that BioDelivery Sciences International will post $-0.59 EPS for the current fiscal year.
BioDelivery Sciences International, Inc (NASDAQ:BDSI) is a specialty pharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.